

Clinical trials of exenatide weekly

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
exenatide weekly vs placebo (add on MET)			
Kim , 2007 [NCT00103935] n=30/15 follow-up: 15 weeks	exenatide LAR 0.8 or 2 g daily versus Placebo on-top of metformin	subjects with type 2 diabetes suboptimally controlled with metformin and/or diet and exercise	Parallel groups double blind
exenatide weekly vs insulin glargine			
DURATION-3 (Diamant) , 2010 [NCT00641056] n=233/223 follow-up: 26 weeks	exenatide (2 mg, once-a-week injection) versus insulin glargine once-daily injection	adults with type 2 diabetes who had suboptimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for 3 months or longer	Parallel groups open (blind analysis) USA, Puerto Rico, Europe, Russia, Australia, Korea, Taiwan, Mexico
exenatide weekly vs pioglitazone			
DURATION-2 (Bergental) (vs pioglitazone) , 2010 [NCT00637273] n=170/172 follow-up: 26 weeks	2 mg injected exenatide once weekly plus oral placebo once daily versus 45 mg oral pioglitazone once daily plus injected placebo once weekly	-	Parallel groups double blind USA, India, and Mexico
exenatide weekly vs sitagliptin			
DURATION-2 (Bergental) (vs sitagliptin) , 2010 [NCT00637273] n=170 follow-up: 26 weeks	2 mg injected exenatide once weekly plus oral placebo once daily versus 100 mg oral sitagliptin once daily plus injected placebo once weekly	patients treated with metformin	double blind USA, India, and Mexico
exenatide weekly vs liraglutide			
H80-MC-GWDE <i>ongoing</i> [NCT01029886] n=NA follow-up: 36 weeks	exenatide once weekly for 26 weeks versus once-daily liraglutide for 26 weeks	-	open argentina

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>

- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>

References

Kim, 2007:

Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care* 2007;30:1487-93 [[17353504](#)] [10.2337/dc06-2375](#)

DURATION-3 (Diamant), 2010:

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *Lancet* 2010 Jun 26;375:2234-2243 [[20609969](#)] [10.1016/S0140-6736\(10\)60406-0](#)

DURATION-2 (Bergental) (vs pioglitazone), 2010:

Wysham C, Bergental R, Malloy J, Yan P, Walsh B, Malone J, Taylor K DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. *Diabet Med* 2011 Mar 22;: [[21434995](#)] [10.1111/j.1464-5491.2011.03301.x](#)

DURATION-2 (Bergental) (vs sitagliptin), 2010:

Bergental RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet* 2010 Jun 25;: [[20580422](#)] [10.1016/S0140-6736\(10\)60590-9](#)

H8O-MC-GWDE, 0:

ongoing trial NCT01029886

Entry terms: exenatide, exenatide, bydureon, exendin-4, Ex4 peptide, exendin 4, AC 2993 LAR, Byetta, AC 2993,